Issue 37, 2025, Issue in Progress

Synthesis of some new pyrimidine-based pyrene/benzochromene hybrids as EGFR kinase inhibitors in HCT-116 cancer cells through apoptosis

Abstract

A series of new pyrimidine-pyrene hybrids 4, naphtho[1,2-g][1,3,5]oxadiazocine 11 (15), and benzo[5,6]chromeno[4,3-d]pyrimidin-5-one 12 (16) were synthesized via a multicomponent one-pot Biginelli-like synthetic protocol. All the new structures were elucidated using elemental and spectroscopic techniques (1H- and 13C-NMR, HRMS, MALDI-TOF, IR). The cytotoxicity of the new compounds was evaluated against “HCT-116, HepG2, and WI-38” cell lines. Compounds 4b and 4c demonstrated the best inhibitory potency against HCT-116 cancer cells, where their IC50 values were 1.34 μM and 1.90 μM, compared to Erlotinib with an IC50 value of 1.32 μM. Further, compounds 4a and 16 showed substantial cytotoxic effects on HCT-116 cancer cells, with IC50 values of 4.8 and 6.46 μM, respectively. Regarding the EGFR inhibition, compounds 4b and 4c exhibited IC50 values of 77.03 nM and 94.9 nM, respectively, compared to Erlotinib (IC50 = 72.3 nM). Compound 4b treatment induced apoptosis in HCT-116 cancer cells by 30.2-fold, arresting the cell cycle at the G1-phase. It upregulated the apoptosis-related genes using the RT-PCR. Finally, a molecular docking study highlighted the binding interactions with key amino acids inside the EGFR binding site.

Graphical abstract: Synthesis of some new pyrimidine-based pyrene/benzochromene hybrids as EGFR kinase inhibitors in HCT-116 cancer cells through apoptosis

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Paper
Submitted
22 May 2025
Accepted
16 Aug 2025
First published
28 Aug 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 30683-30696

Synthesis of some new pyrimidine-based pyrene/benzochromene hybrids as EGFR kinase inhibitors in HCT-116 cancer cells through apoptosis

Y. A. A. Mohammed, N. A. Kheder, M. S. Nafie, A. A. Abbas and K. M. Dawood, RSC Adv., 2025, 15, 30683 DOI: 10.1039/D5RA03611A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements